Big Phar­ma’s busi­ness mod­el is bro­ken; New drug OKs plunged this year, high­light­ing an ug­ly re­al­i­ty

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Big Phar­ma …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.